Dramatic success in cancer immunotherapy has been achieved over the last decade with
the introduction of checkpoint inhibitors, leading to response rates higher than with …

Therapeutic cancer vaccines have been a subject of research for several decades as
potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and …

With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint
inhibitors, strategies to improve the response rate and duration of current cancer …

The findings, reported earlier this year, have revitalized the cancer vaccine community,
inspiring companies to intensify efforts to stimulate the immune system to recognize tumour …

The promise of immune-based therapies to treat cancer has been realized over the last
several years with several breakthrough therapies, including T-cell checkpoint inhibitors and …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Tumor vaccines have been an attractive concept in the immunotherapy of cancer based on
the central role of tumor-associated antigens in allowing the immune system to recognize …

Abstract The Cancer Moonshot aspires to cut the death rate from cancer by at least 50%
over the next 25 years by 2047 and improve the experience of people and their families …

Current excitement about cancer immunotherapy is the result of unprecedented clinical
impact from immune checkpoint inhibitors, particularly those that target programmed death …

Immunotherapy is emerging as a promising anti-cancer curative modality. However, in
contrast to recent advances obtained employing checkpoint blockade agents and T cell …